SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Gorilla and King Portfolio Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Apollo who wrote (11839)12/3/1999 8:00:00 AM
From: Jill  Read Replies (1) of 54805
 
Stan, you phrased that very well about biotech...also, from what little I know, genes often work in concert, so there may not be as many eventual magic bullets as we'd hope. But, bp, it is indeed completely fascinating if an unstable & risky investing area at this point. For a while I was invested in Sepracor, which had a nice biotech story: they scooped up the patents to a lot of drugs, many of them biggies, and refined them to have less side effects and/or be more potent. This allowed major companies to partner with Sepracor to call the drug "new" when their patent expired and the generics came in, and thus hold onto market share. It seemed a great story, relying on known and successful drugs and it was a momentum play for a while; I haven't followed it lately, but even then the company was far slower and rockier than our gorillas in high tech, and was not expected to even turn a profit for several years.

Jill
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News